Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03656692 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
A Phase 4 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03656692: Clinical Trial Phase 4 study, sponsored by Mallinckrodt.
NCT03656692 is a Phase 4 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03656692, a Phase 4 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
Primary Outcome
The Nussenblatt grading scale uses photographic measurement of cloudy, declining vision (vitreous haze). The scale goes from 0 to 4, and lower scores are better.
Interventions
- DRUG Acthar Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2020-07-14 |
| Phase | Phase 4 |
Why NCT03656692 stopped before completion
NCT03656692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Acthar Gel is the first listed.
NCT03656692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03656692 about?
NCT03656692 is a clinical study titled "Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)". The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
What is the current status of trial NCT03656692?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2018-10-05. Estimated completion is 2020-07-14.
What interventions are being tested in trial NCT03656692?
The interventions under investigation include: Acthar Gel (DRUG).
Who is sponsoring clinical trial NCT03656692?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03656692's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI